Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative ...

Beam is a pioneer of the base-editing approach to gene-editing, which can be used to convert one nucleotide base into another without cutting both strands of DNA, unlike other technologies like ...

Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin deficiency (AATD), Beam Therapeutics is seeking to ...

Beam’s therapy employs base editing to perform an in vivo correction of the mutation at the root of the inherited disease.